3B Future Health Fund

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

Geneos Therapeutics, Inc. is a biotechnology company that specializes in the development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and located in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies based on the unique tumor mutations of individual patients. By identifying relevant neoantigen targets from each patient's tumor, Geneos aims to develop innovative treatments that provide targeted immunotherapy options for various types of cancer. This approach is designed to empower oncologists with tailored solutions to improve patient outcomes in cancer treatment.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.

Roca Therapeutics is a biotechnology company dedicated to the research and development of innovative therapeutics aimed at treating severe, life-threatening diseases associated with hypervascularization and the immunosuppressive effects of M2 macrophages. The company focuses on creating small molecule medicines and novel anti-cancer strategies that target key factors in tumor development, aggressiveness, chronic inflammation, and tumor cell proliferation. By addressing these critical areas, Roca Therapeutics aims to provide patients with new treatment options for rare cancers, ultimately offering them a renewed chance at life.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Kither Biotech, established in 2011 and based in Turin, Italy, specializes in researching and developing drugs targeting pulmonary diseases with unmet medical needs. Its primary focus is on two internally developed compounds: KIT2014, a peptide currently in pre-clinical development for treating cystic fibrosis, which has received orphan drug designation from the EMA; and CL27, a molecule intended for chronic obstructive pulmonary diseases and allergic asthma, also in its pre-clinical phase.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

GenEp, Inc. is a pre-clinical stage biotechnology company that focuses on developing therapies for rare genetic epilepsies and other treatment-resistant forms of epilepsy. The company leverages its intellectual property assets to create selective compounds aimed at modulating sodium and other ion channels associated with these conditions. By targeting specific mutations within these channels, GenEp seeks to enable medical professionals to develop effective treatment options tailored to meet the unique medical needs of patients suffering from these challenging disorders.

GreenBone specializes in the development of innovative bone implants derived from bamboo wood, designed to address severe fractures and conditions that lead to significant bone loss, such as trauma and tumors. The company’s technology transforms bamboo into hydroxyapatite, a widely utilized biomaterial that serves as a bone graft scaffold. These biomimetic, reabsorbable implants possess the necessary weight-bearing and bone regeneration properties to effectively treat non-union fractures. Founded by a research group from ISTEC-CNR of Faenza, GreenBone aims to provide bio-inspired solutions that can significantly improve patient outcomes in orthopedic care.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Gain Therapeutics is a biotechnology company focused on developing pharmacological chaperone drugs to treat rare metabolic disorders and other diseases. Headquartered in Bethesda, MD, the company employs its proprietary Magellan platform to discover novel allosteric binding sites on proteins associated with various conditions, including lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. Gain Therapeutics' clinical-stage candidate, GT-02287, is aimed at treating GBA1 Parkinson's disease. By utilizing Minoryx Direct Enzyme Therapy, the company aims to provide innovative solutions that stabilize misfolding mutations and restore the enzymatic activity of lysosomal enzymes, addressing high unmet medical needs, particularly in pediatric genetic disorders. Established in 2017, Gain Therapeutics is committed to advancing therapeutic options for patients with challenging health conditions.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

QuantuMDx Group Limited is a medical device company focused on developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and labs. Founded in 2008 and based in Newcastle upon Tyne, UK, the company offers innovative products like Q-POC, a battery-operated molecular diagnostic device that delivers quick sample-to-result testing for a range of samples, including blood, tissue, and urine, in just 10 to 30 minutes. Additionally, QuantuMDx has created the Internet of Life, a real-time global pathogen monitoring system. Its diagnostic tools are utilized for applications such as warfarin prediction testing, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panels. By providing accessible diagnostic solutions, QuantuMDx supports personalized medicine initiatives across both developed and developing regions.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

GreenBone specializes in the development of innovative bone implants derived from bamboo wood, designed to address severe fractures and conditions that lead to significant bone loss, such as trauma and tumors. The company’s technology transforms bamboo into hydroxyapatite, a widely utilized biomaterial that serves as a bone graft scaffold. These biomimetic, reabsorbable implants possess the necessary weight-bearing and bone regeneration properties to effectively treat non-union fractures. Founded by a research group from ISTEC-CNR of Faenza, GreenBone aims to provide bio-inspired solutions that can significantly improve patient outcomes in orthopedic care.

QuantuMDx Group Limited is a medical device company focused on developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and labs. Founded in 2008 and based in Newcastle upon Tyne, UK, the company offers innovative products like Q-POC, a battery-operated molecular diagnostic device that delivers quick sample-to-result testing for a range of samples, including blood, tissue, and urine, in just 10 to 30 minutes. Additionally, QuantuMDx has created the Internet of Life, a real-time global pathogen monitoring system. Its diagnostic tools are utilized for applications such as warfarin prediction testing, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panels. By providing accessible diagnostic solutions, QuantuMDx supports personalized medicine initiatives across both developed and developing regions.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

QuantuMDx Group Limited is a medical device company focused on developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and labs. Founded in 2008 and based in Newcastle upon Tyne, UK, the company offers innovative products like Q-POC, a battery-operated molecular diagnostic device that delivers quick sample-to-result testing for a range of samples, including blood, tissue, and urine, in just 10 to 30 minutes. Additionally, QuantuMDx has created the Internet of Life, a real-time global pathogen monitoring system. Its diagnostic tools are utilized for applications such as warfarin prediction testing, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panels. By providing accessible diagnostic solutions, QuantuMDx supports personalized medicine initiatives across both developed and developing regions.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.